image

Welcome to Remedium Bio Corporate News and Investor Information!

Remedium is a Boston based pre-clinical stage Biotechnology company driven by a single basic principle - we believe that any disease can be cured. In line with this principle, Remedium strives to develop life-changing therapeutics for a broad range of diseases, one treatment at a time - a brilliant today for a better tomorrow.

Remedium Corporate News

  • 2024-2023

    • Remedium invited to present at the 15th Strategic Drug Discovery Summit – 02/24

      BOSTON, Feb 27, 2024 – Remedium Bio announced today that the company was invited to give a keynote podium presentation at the 15th Drug Discovery Strategic Summit (DDSS). This year’s DDSS is taking place May 8th and 9th at the Embassy Suites, Hilton, Boston. The event is focused on disruptive drug discovery, pharma and biotech partnerships, collaboration, and innovation in the fields of cell and gene therapies, recombinant proteins, and small molecule pharmaceuticals. Remedium will present data from its AI-powered high-throughput screening Prometheus™ platform, which enables drug discovery from target to in vivo efficacy in as little as 6 months.

      “We are honored by the invitation to present a keynote talk at the 15th Strategic Drug Discovery Summit” said Frank Luppino, President and CEO of Remedium. “Our team will present Remedium’s innovative approach to drug discovery and the application of the Prometheus™ first-in-class dose adjustable gene therapy platform to the rapid advancement of biologics through preclinical efficacy”.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium to present at the 4th Annual Next Generation Gene Therapy Vectors Summit – 02/24

      BOSTON, Feb 19, 2024 – Remedium Bio is excited to announce that the company has been invited to present at the 4th Annual Next Generation Gene Therapy Vectors Summit in Boston, MA. Remedium will highlight its Prometheus™ dose adjustable gene therapy platform technology and the lead candidate RMD1202, a disease modifying gene therapy for the treatment of type 2 diabetes and obesity. RMD1202 is the only single injection gene therapy treatment candidate for type 2 diabetes and obesity with the possibility of dose adjustment following initial administration. In addition to the significant advantages in cost over current alternatives, RMD1202 provides the possibility to eliminate pharmacokinetic spike related gastrointestinal side effects, which are associated with current multi-dose approaches. Remedium’s podium presentation titled “Prometheus™: The First Adjustable Dose Gene Therapy Platform Technology” will be presented on Jun 14 at 11:00 am ET.

      “We are grateful for the invitation to present our dose adjustable gene therapy platform technology – Prometheus™ at the 4th Annual Next Generation Gene Therapy Vectors Summit in Boston”, said Frank Luppino, President and CEO of Remedium. “We aim to validate this revolutionary technology in a first-in-human study of RMD1202, a single injection treatment for type 2 diabetes and obesity”.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Evidence of RMD1101 disease modification published in Current Gene Therapy – 02/24

      BOSTON, Feb 5, 2024 – Remedium announced today the publication of a manuscript titled “Single Injection AAV2-FGF18 Gene Therapy Reduces Cartilage Loss and Subchondral Bone Damage in a Mechanically Induced Model of Osteoarthritis” in the peer reviewed journal Current Gene Therapy.

      Osteoarthritis (OA) is a chronic degenerative disease characterized by progressive loss of cartilage, leading to pain, loss of function, and disability. Affecting an estimated 500 million people around the globe, OA is the largest unmet clinical need in rheumatology, with no currently approved disease modifying treatments.

      RMD1101 is a novel, investigational gene therapy and is the only single-injection treatment based on the regenerative mechanism of the FGF18 protein. The findings highlighted in the study demonstrate an unprecedented effect on disease progression, and a unique set of advantages of the gene therapy approach to treating Osteoarthritis.

      Key highlights include:

      - High treatment localization within the joint capsule and long-term durability following intra articular AAV2-FGF18 delivery.

      - Significant protection of hyaline cartilage after a single injection of RMD1101 (AAV2-FGF18), superior to chondroprotection achieved by the repeat FGF18 protein treatment regimen.

      - Improved safety profile compared to intra-articular protein injections, as a result of the single injection treatment paradigm, which prevents repeat joint capsule disruption.

      - Protection of natural subchondral bone architecture from osteoarthritic remodeling and prevention of subchondral bone void formation.

      - Improved gene expression, which results in the maintenance and homogeneity of the critical hyaline cartilage boundary layer lubricating protein PRG4 (lubricin).

      “We are honored to have Current Gene Therapy publish our manuscript highlighting RMD1101’s unique safety and efficacy profile” said Frank Luppino, President and CEO of Remedium. “The study findings confirm the advantages of gene therapy over repeat protein injection regimens, providing hope that a single-injection, truly disease modifying treatment for osteoarthritis may be a future possibility for patients”.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium announces the appointment of James Carroll as Chief Business Officer – 01/24

      BOSTON, Jan 23, 2024 – Remedium Bio today announced the appointment of James Carroll as the Chief Business Officer. In this position, Jim will lead partnership and collaboration efforts for Remedium’s Prometheus™ dose adjustable gene therapy platform technology.

      “We are excited to welcome Jim to the Remedium team, to help us fully realize the potential of our first-in-class platform technology” said Frank Luppino, President and CEO of Remedium. “Jim’s background and capabilities in fundraising, business development, and corporate strategy will be instrumental in the next phase of Remedium’s evolution”.

      Jim brings over 20 years business development, commercial, and fundraising experience to Remedium, having held prior roles of increasing responsibilities at companies including Repligen, Millipore, Waters, and Bio-Rad. In addition to Jim’s extensive industry experience, he is the Founder and General Partner at Boston Life Science Investments and Managing Director of Wharton Alumni Angels for Lifesciences. With a background in Organic Chemistry and MBA from Northeastern University, and holding a broad array of certifications from MIT, Harvard Medical School, and Harvard Business School, Jim brings extensive corporate strategy, business development, and fundraising expertise to Remedium Bio.

      “I am excited by the opportunity to join the Remedium team, and to help usher in the next generation of gene therapy with this disruptive technology,” said Jim. “In parallel, Remedium’s internal programs are targeting a number of large clinical needs with unique safety and efficacy advantages over the current gold standard treatments and investigational approaches”.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium abstract accepted for the 2024 ORS conference – 01/24

      BOSTON, Jan 16, 2023 – Remedium Bio announced today the acceptance of an abstract titled “AAV2-FGF18 gene therapy protects against cartilage loss and subchondral bone remodeling in a mechanically induced model of osteoarthritis” for the 2024 Orthopedic Research Society (ORS) Annual Meeting. This year’s ORS annual meeting will take place in Long Beach, California February 2nd through the 6th at the Long Beach Convention Center. This 70th anniversary event will bring together an estimated 2,500 orthopedic thought leaders from academia and industry, to review the most current clinical and preclinical research in the field of musculoskeletal disorders.

      “We are honored by the selection to present our abstract at this year’s inaugural event and looking forward to highlighting our most recent findings on the safety and efficacy of RMD1101, the only single injection disease modifying osteoarthritis therapy based on the mechanisms of FGF18” said Frank Luppino, President and CEO of Remedium.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium invited to the 2024 GenScript Biotech Global Forum – 11/23

      BOSTON, Nov 20, 2023 – Remedium Bio is pleased to announce that the company has been invited to attend the 2024 GenScript Biotech Global Forum. Remedium’s Chief Operating Officer, Alex Goraltchouk will represent the company at this event, which is taking place during the 42nd J.P. Morgan Healthcare Conference in Grand Hyatt San Francisco on Wednesday January 10. The main panel discussion will focus on next generation gene therapy and disruptive technologies that are anticipated to revolutionize this therapeutic modality. The theme of the Biotech Global Forum is focused on "Innovation & Breakthroughs” shaping the future of Gene and Cell Therapy. The event is anticipated to be widely attended by leaders from the R&D, capital community, as well as representatives from the regulators and academia to discuss technological breakthroughs, commercialization challenges, and current regulatory trends.

      “I am honored by the invitation and excited to attend GenScript’s flagship event for the gene and cell therapy industry”, said Alex Goraltchouk, COO of Remedium Bio. “Remedium’s first-in-class adjustable dose gene therapy platform - Prometheus™ is a premier example of a next generation gene therapy that will help shape the future of medical treatment”.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium abstract accepted for the 7th International Neurology and Brain Disorders Conference – 11/23

      BOSTON, Nov 2, 2023 – Remedium Bio announced today the acceptance of an abstract titled “Treatment with rhFGF18 Appears Cerebroprotective in Model of Ischemic Stroke” at the 7th International Neurology and Brain Disorders Conference. This year INBD event is taking place virtually and in person in Dubai, UAE and Remedium will present its work as a virtual podium talk. This year’s conference theme is “Integrated Approach for Identifying Solutions in the Field of Neurology and Brain Disorders” and covers interventional pharmaceutical and biological treatments for ischemic and hemorrhagic stroke. Remedium will highlights its pipeline candidate RMD1501, which has shown potential for increased survival, improved motor cognitive function, and neuro- and cerebro-protection in a well-characterized model of transient cerebral ischemia.

      “We are honored to have been selected to present at the 7th International Neurology and Brain Disorders Conference” said Frank Luppino, President and CEO of Remedium. “The invitation to present our novel investigational candidate for the treatment of ischemic stroke, as a virtual podium talk at this event, highlights the advances made by our team on the development of Remedium’s pipeline asset for the treatment of cerebral ischemia”.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium selected as finalist for Boehringer Ingelheim Innovation Day – 10/23

      BOSTON, Oct 16, 2023 – Remedium Bio is excited to announce that the company has been selected as a finalist for the in-person pitch competition at the upcoming Boehringer Ingelheim (BI) External Innovation Day. This year’s BI Innovation Day will take place on Oct 26th at the Boehringer Ingelheim Biopharmaceuticals Business Unit headquarters at Fremont, California. Remedium will present its Prometheus™ dose adjustable gene therapy platform technology – a first-in-class system, which enables ultra-low-cost delivery of virtually any subcutaneously administered biologic, as a single injection adjustable dose gene therapy. The company will also highlight progress on its pipeline candidate for the treatment of Type 2 Diabetes and Obesity RMD1202 – a single injection, adjustable dose, subcutaneously administered GLP-1 Receptor Agonist gene therapy.

      “We are very honored to have been selected amongst the finalists for this highly competitive and prestigious event” said Frank Luppino, President and CEO of Remedium. “We look forward to presenting our novel platform and in vivo efficacy results for its first indication in a translatable model of Type 2 Diabetes and Obesity”.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium announces abstract acceptance for the 8th International Conference on Neurology – 09/23

      BOSTON, Sep 19, 2023 – Remedium Bio announced today the acceptance of an abstract describing the safety and efficacy of an investigational neuroprotective treatment for ischemic stroke RMD 1501. The abstract titled “Treatment with rhFGF18 appears cerebroprotective in model of ischemic stroke” was accepted for opening day podium presentation at the 8th Edition of International Conference on Neurology and Brain Disorders (INBC) taking place in Boston, October 19th through the 21st. This year’s INBC event is focusing on the theme of BRAIN “Bolstering & Renovating Advanced techniques In Neurology” with an emphasis on neuroprotective and neuroregenrative therapeutics for the treatment of brain disorders.

      “We are honored to have been accepted to present our abstract as an opening day podium talk at the 2023 INBC in Boston” said Frank Luppino, President and CEO of Remedium, “The acceptance of our abstract for such a high-profile event highlights the advances made by the team on the development of Remedium’s pipeline asset for the treatment of cerebral ischemia”.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Prometheus™ abstract accepted for the American Society of Human Genetics conference – 09/23

      BOSTON, Sep 5, 2023 - Remedium Bio announces the acceptance of an abstract titled “Development of a novel lipid nanoparticle-based adjustable gene therapy platform technology” for the 2023 American Society of Human Genetics (ASHG) annual conference. This year’s 75th anniversary ASHG will take place in Washington, DC on November 1st through 5th as a live, in-person event. The work presented will unveil Remedium’s dose adjustable gene therapy platform technology - Prometheus™. The revolutionary gene therapy system developed by Remedium, is a first-in-class, ultra-low cost, dose adjustable gene therapy platform intended for replacing subcutaneous protein injection regimens with a single treatment gene therapy. The system is designed with unique tropism and optimized to eliminate pharmacokinetic sawtoothing related side-effects and suboptimal efficacy profiles associated with many injectable protein therapies.

      The American Society of Human Genetics is a professional, scientific, and medical society, which includes over 8,000 scientists from over 80 countries with the goal of translating new genetic knowledge to propel biomedical research. This year’s event is anticipating over 5,000 attendees and over 3,000 presented conference posters.

      “We are honored to have been accepted to present our abstract as a podium talk at the 75th annual ASHG” said Frank Luppino, President and CEO of Remedium, “The acceptance of our abstract for such a selective meeting highlights the advances made by the team on the development of Remedium’s revolutionary, first-in-class, dose adjustable gene therapy platform technology”.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium awarded National Science Foundation (NSF) innovation grant – 08/23

      BOSTON, Aug 1, 2023 - Remedium Bio announces the receipt of a National Science Foundation (NSF) Phase I Small Business Innovation Research (SBIR) grant to support the development of the Prometheus™ dose-adjustable gene therapy platform technology.

      Prometheus™ is a first-in-class dose-adjustable gene therapy platform technology capable of providing a safe, durable, and low-cost alternative to repeat subcutaneous injections of recombinant proteins. Initial proof of concept studies demonstrate that the platform is well tolerated, capable of producing therapeutic levels of transgene expression, and results in potential pharmacokinetic advantages over repeat protein injection treatments.

      The NSF grant will enable the advancement of the Prometheus™ platform to its first therapeutic application for the treatment of Type 2 Diabetes and Obesity. Phase I SBIR awardees are eligible to apply for subsequent Phase II awards of up to $1.0 million.

      “We are extremely excited to have been selected for this prestigious award from the National Science Foundation” said Frank Luppino, President and CEO of Remedium. “We believe that the Prometheus™ platform can revolutionize gene therapy as a therapeutic modality and the NSF’s high recognition of this technology is further supportive of its significant promise.”

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium abstract accepted at the 7th International Conference on Neurology – 6/23

      BOSTON, Jun 1, 2023 - Remedium Bio, a biotechnology company developing advanced therapies in the fields of rheumatology, endocrinology, and neurology, today announced the acceptance of an abstract entitled “rhFGF18 and rhGDF11 for the Treatment of Ischemic Stroke” for the 2023 International Conference on Neurology and Neurological Disorders. This year’s conference is organized in collaboration with the Journal of Integrative Neuroscience and will take place in Rome, Italy June 16th and 17th as a live in-person or virtual online event. The work presented will highlight Remedium’s progress in the development of a novel treatment for ischemic stroke. This year’s Magnus Group event includes tracks on Neurological Disorders and Stroke, Brain Injury and Behavioral Neuroscience, as well as Clinical and Translational Neurology.

      “We are honored to have been accepted to present our abstract reviewing the progress made to date in the development of our innovative treatment for the management of ischemic stroke” said Frank Luppino, President and CEO of Remedium, “The acceptance of our abstract at this prestigious meeting highlights the advances made by the team on the development of Remedium’s innovative pipeline of disease modifying therapies for age-related pathologies”.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium abstract accepted for the 8th Skeletal Research Symposium at MGH – 5/23

      BOSTON, May 1, 2023 - Remedium Bio, a biotechnology company developing advanced therapies in the fields of rheumatology, endocrinology, and neurology, today announced the acceptance of an abstract entitled “FGF18 Gene Therapy Treatment for Osteoarthritis Promotes Regenerative Chondroanabolic and Anti-Catabolic Activity” for the 8th Annual Skeletal Research Symposium (ASRS). This year’s ASRS will take place on May 8th, in Boston, as a live in-person event at the Mass General Hospital (MGH) Main Campus. The work presented will highlight Remedium’s progress in the development of a novel potentially disease modifying treatment for Osteoarthritis, which is based on the chondrogenic mechanism of FGF18. The abstract will highlight the latest safety, efficacy, durability, and mechanistic findings from the preclinical studies comparing a single injection FGF18 gene therapy treatment to a series of protein injections and a placebo control.

      “We are very excited for the opportunity to present our work at the 8th Annual Skeletal Research Symposium” said Frank Luppino, President and CEO of Remedium, “The acceptance of our abstract for this prestigious, MGH-organized event, highlights the advances made by the team on the development of Remedium’s first-in-class potentially disease modifying gene therapy for Osteoarthritis”.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium abstract accepted at the 2023 American Academy of Neurology Conference – 4/23

      BOSTON, Apr 10, 2023 - Remedium Bio, a biotechnology company developing advanced therapies in the fields of rheumatology, endocrinology, and neurology, today announced the acceptance of an abstract entitled “Treatment with rhFGF18 Analog Results in Cerebroprotection and Recovery of Motor and Memory Function in a Rat Model of Acute Ischemic Stroke” for the 2023 American Academy of Neurology (AAN) annual meeting. This year’s AAN will take place in Boston, Massachusetts April 22nd through the 27th as a live in-person or virtual online event. The work presented will highlight Remedium’s progress in the development of a novel treatment for ischemic stroke. The American Academy of Neurology is a professional, scientific, and medical society established in 1948 with a current membership of over 38,000 scientists and clinical researchers representing the fields of neurology, neuroimmunology, and neural genetics.

      “We are honored to have been accepted to present our abstract reviewing the progress made to date in the development of our innovative treatment for the management of ischemic stroke at 2023 AAN” said Frank Luppino, President and CEO of Remedium, “The acceptance of our abstract at such a prestigious conference highlights the advances made by the team on the development of Remedium’s innovative pipeline of disease modifying therapies”.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium appoints Dr. Charles Sherwood to Corporate Advisory Board – 04/23

      BOSTON, Apr 5, 2023 - Remedium Bio is pleased to announce the appointment of Charles Sherwood, Ph.D., as a Corporate Advisor for the company. Dr. Sherwood brings a wealth of experience building companies that have created significant value developing products for Osteoarthritis and cartilage regeneration. Dr. Sherwood will advise on corporate strategy and the company’s lead candidate disease modifying gene therapy for Osteoarthritis.

      Dr. Sherwood is the Founder of Sherwood Ventures, a firm focused on early-stage life science company investments. Dr. Sherwood was previously the CEO of Anika Therapeutics, a global, publicly traded regenerative medicine company engaged in the discovery, preclinical and clinical development, approval, and commercialization of restorative and regenerative treatments, with a focus in Rheumatology. Dr. Sherwood brought to the market leading OA palliative therapies including Monovisc®, Orthovisc®, and Cingal®. In addition, he led the development and industrialization of Hyalofast®, a single-step cartilage regenerative solution for focal cartilage defects. Under his leadership, the OA-focused company with a $6M market cap grew to a highly-profitable multinational corporation with a distribution network in over 85 countries.

      "We are extremely excited to onboard Dr. Sherwood in this important advisory role at this transformational inflection point for Remedium” said Frank Luppino, President and CEO of Remedium Bio. “We look forward to levering Dr. Sherwood’s deep experience and business expertise in rheumatology, product development, and strategic partnering as we continue to advance our lead disease-modifying Osteoarthritis product and novel platform technology”.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium and Exothera partner on scale-up and demonstration runs for AAV2-FGF18 – 3/23

      BOSTON, Mar 22, 2023 - Remedium Bio, a biotechnology company developing a lead candidate disease modifying treatment for Osteoarthritis (OA), and Exothera S.A., a full-service Contract Development and Manufacturing Organization (CDMO) specialized in gene therapy, vaccines, and oncolytic viruses, reached an agreement for a collaboration to demonstrate the industrialization potential of Remedium’s AAV2-FGF18.

      Remedium’s lead candidate is the only disease modifying gene therapy based on the clinically proven regenerative mechanism of FGF18. OA is the largest unmet clinical need in rheumatology, with no currently approved disease modifying treatments and an estimated 300-500 million patients around the globe. Remedium’s recent development progress, demonstrating strong safety and efficacy potential in a translatable preclinical model, was recently presented at the 2023 Orthopaedic Research Society meeting, 2023 OARSI World Congress, and the 2022 American Society for Bone and Mineral Research meeting.

      Exothera is a highly experienced viral vector manufacturer, with demonstrated capabilities in large-scale AAV production, achieving state-of-the art titers and quality. Boasting an existing 160,000 sq. ft. high-tech manufacturing centre of excellence in Jumet, Belgium, Exothera is well-positioned to supply Remedium's lead candidate for clinical studies and at commercial scale. Exothera can count on state-of-the-art technology and an extensive set of experts in AAV-based viral vector production. The CDMO will execute a proof of concept for transient expression of Remedium’s AAV2-FGF18 with suspension culture, based on a HEK-293 cell line. Exothera will focus on identifying a high yield production process and reduce cost of goods for the manufacturing process of Remedium’s AAV2-FGF18.

      Hanna Lesch, Chief Technology Officer at Exothera: “It is wonderful to engage in a new challenge to apply the exoREADY™ platform to a first-in-class gene therapy for Osteoarthritis. We have already achieved promising results with other AAV-based gene therapies, and we are confident that we can play our part in making a better life for patients”.

      Frank Luppino, President, and CEO of Remedium: “With several recently approved cell and gene therapy products advancing to the market, gene therapy is transcending the realm of rare monogenic disorders to enable treatment of large unmet clinical needs like Osteoarthritis. Remedium’s recently published preclinical results uniquely position the company to advance this transformative therapy to the clinic. We are very excited to be able to partner with Exothera on this project to advance our lead candidate through preclinical toxicology studies and eventually human clinical trials.”

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium and Biovian agree to collaborate on first-in-class disease modifying AAV – 3/23

      BOSTON, Mar 16, 2023 - Remedium Bio, a Boston-area gene therapy company developing treatments for a range of large clinical unmet needs in rheumatology, endocrinology, and age-related diseases, and Biovian Oy, a globally operating Nordic CDMO for biopharmaceuticals, have agreed on a collaboration for AAV drug development. The agreement covers Remedium’s lead candidate, a first-in-class disease-modifying treatment for Osteoarthritis (OA) under the name RMD 1101. Biovian has agreed to include Remedium’s lead candidate in Biovian’s AAV manufacturing platform development program. Biovian’s second-generation AAV platform will be built around a selected high-productivity and state-of-the-art quality suspension-based HEK293 cell line, with full scalability to 200L and utilizing chromatography for standard purification. Biovian has invented a robust way to efficiently separate full capsids from empty capsids, applicable to large-scale manufacturing.

      Antti Nieminen, CEO at Biovian: "We are pleased to start a collaboration with Remedium Bio and to include Remedium’s AAV candidate in our ongoing second-generation AAV platform development program. Remedium’s therapeutic candidate will be important in the validation of Biovian’s second generation AAV platform – bringing a new level of quality and efficiency to the viral vector manufacturing space”.

      Frank Luppino, President and CEO at Remedium Bio: “Having recently generated one of the most comprehensive preclinical efficacy datasets in Osteoarthritis and presented at the 2023 Orthopedic Research Society meeting, we are extremely excited to scale production of our lead candidate RMD1101 to support Toxicology and Clinical demand. Partnering with Biovian’s high-productivity viral vector manufacturing process will enable clinical supply and cost-effective production at eventual commercial scale for a disease that impacts hundreds of millions of people around the globe.”

      About Biovian

      Biovian is a Contract Development and Manufacturing Organization, CDMO that provides premium services to biotech companies developing innovative gene therapies and biopharmaceuticals. The goal of the company is to turn ideas into products by taking client projects from the laboratory bench to the clinic. Biovian offers its clients One-Stop-Shop GMP CDMO services, with modularity available from gene to finished vial. Biovian is especially focusing on viral vector production and microbial production of recombinant proteins and GMP plasmid DNA. Guided by its Nordic ethos Biovian has established a reputation for delivering high-quality work on time and within budget to a global client base. Additional information is available at www.biovian.com.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Data demonstrating safety and chondrogenic activity of RMD1101 published in Cartilage – 3/23

      BOSTON, Mar 13, 2023 - Remedium Bio, a gene therapy company developing novel treatments for significant unmet needs, today announced the publication of pre-clinical data demonstrating the safety and chondrogenic activity of RMD1101, its innovative gene therapy for Osteoarthritis. These data are the first to be published from Remedium’s ongoing research collaboration with Tufts University studying the approach. The paper, entitled “Adeno-Associated Virus-Delivered Fibroblast Growth Factor 18 Gene Therapy Promotes Cartilage Anabolism” will be published in Volume 14, Issue 1 of the journal Cartilage, and is available OnlineFirst.

      Key Points

      - AAV2-FGF18 appears to have a wide therapeutic safety window and is able to induce chondrogenesis at very low, locally administered doses

      - The FGF18 gene therapy appears to induce chondrogenesis by increasing hyaline cartilage associated gene expression and promoting chondrocyte proliferation

      - RMD1101 appears safe and effective at promoting cartilage anabolism in vivo, following a single intra articular injection

      “Having these results published in Cartilage provides important external validation of their significance” said Frank Luppino, President and CEO of Remedium. “Our findings confirm the chondrogenic mechanism after a single injection of RMD1101 and provide preliminary confirmation for the potential of the gene therapy approach to treating Osteoarthritis.” RMD1101 is the only disease modifying gene therapy treatment for Osteoarthritis based on the clinically validated chondrogenic mechanism of FGF18. It is being studied as a single injection treatment for OA in both the human and companion animal markets. “Our results show the promise of treating Osteoarthritis by harnessing the endogenous regenerative power of articular cartilage with a single intra-articular injection FGF18 gene therapy,” said Dr. Li Zeng, PhD, Associate Professor of Immunology at Tufts University School of Medicine. Dr. Zeng is a co-author of the publication and an expert in Osteoarthritis and the molecular and cellular mechanisms of the disease.

      Cartilage is a peer-reviewed, open access journal which publishes articles with a focus on recent discoveries related to the musculoskeletal system and cartilage repair, development, and regeneration. The Sage Publishing group, MEDLINE indexed journal publishes full length original manuscripts covering preclinical and clinical research, and is considered among the top journals in the field of cartilage regeneration.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium announces abstract acceptance for the 2023 TERMIS Conference – 2/23

      BOSTON, Feb 6, 2023 - Remedium Bio, a biotechnology company developing a lead candidate disease modifying treatment for Osteoarthritis (OA), today announced the acceptance of an abstract titled “AAV2-FGF18 Repairs Cartilage in Disease Model of Osteoarthritis” for the 2023 Tissue Engineering Strategies for Human Health and Longevity conference. This year’s event will take place at the Marriott Copley Place in Boston as a live, in-person meeting. The work presented will highlight Remedium’s progress in the development of a novel gene therapy for the treatment of OA, a single-injection treatment potentially capable of reversing cartilage loss in OA. The Tissue Engineering and Regenerative Medicine International Society (TERMIS) is a professional, scientific, and medical society with a mission of advancing tissue engineering and regenerative medicine to generate knowledge with a view to improving patient outcomes.

      “We are honored to have been accepted to present our abstract reviewing the progress made to date in the development of our FGF18 gene therapy treatment for Osteoarthritis at the 2023 Boston TERMIS” said Frank Luppino, President and CEO of Remedium, “We are excited to share the recently generated preclinical safety and efficacy data highlighting the regenerative potential of RMD1101 in the treatment of a range of cartilage pathologies”.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium announces podium presentation abstract acceptance at the VOS – 1/23

      BOSTON, Jan 10, 2023 - Remedium Bio, announces the acceptance of an abstract titled “Novel AAV2-FGF18 Gene Therapy Promotes Cartilage Anabolism” for Podium Presentation at the 50th Annual Veterinary Orthopedic Society (VOS) Conference. This year’s VOS will take place Mar 11-18th at Big Sky, Montana bringing together academics, researchers, and veterinarians to discuss the latest discoveries in veterinary orthopedics, traumatology, and regenerative medicine. The research presented will provide an overview of Remedium’s progress in the development of a novel, potentially disease modifying gene therapy for the treatment of Osteoarthritis, and its advantages specifically for veterinary medicine.

      VOS is the leading veterinary medicine society focused on orthopedics and osteoarthritis, having provided a podium for the presentation of veterinary orthopedic discoveries for over 50 years. The VOS abstracts are published in the Veterinary and Comparative Orthopaedics and Traumatology (VCOT) Journal and made available online at the Veterinary Orthopedic Society website. “We are very excited to have been accepted to present our abstract reviewing veterinary medicine potential of our first-in-class chondrogenic gene therapy treatment for Osteoarthritis at the 2023 VOS” said Frank Luppino, President and CEO of Remedium; “The selection of our abstract for a podium presentation is an important milestone highlighting the progress we have made to date developing this novel treatment and its significant translational potential for the treatment of companion animals”.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

  • 2022-2020

    • Remedium Bio abstract accepted for podium presentation at OARSI – 12/22

      BOSTON, Dec 6, 2022 - Remedium Bio, a biotechnology company developing a lead candidate disease modifying gene therapy for the treatment of Osteoarthritis (OA) announced today the acceptance of an abstract titled “Novel AAV2-FGF18 Chondrogenic Gene Therapy” for the 2023 Osteoarthritis Research Society International (OARSI) conference. The 2023 OARSI World Congress on Osteoarthritis will take place March 17th through 20th in Denver Colorado. The studies presented will provide an overview of Remedium’s progress in the development of a novel gene therapy for the treatment of Osteoarthritis, highlighting the potential of the company’s first-in-class chondrogenic gene therapy treatment.

      OARSI is a leading international medical society for the advancement of understanding, early detection, treatment, and prevention of Osteoarthritis – a highly debilitating disease affecting more than 600 million people worldwide. For over 30 years, OARSI brings together scientists and engineers at the annual World Congress on Osteoarthritis. All abstracts presented at the Congress are published in the supplement to OARSI’s journal, Osteoarthritis and Cartilage. “We are very excited to have been accepted to present our abstract reviewing the safety and efficacy of our first-in-class chondrogenic gene therapy treatment for Osteoarthritis at the 2023 OARSI” said Frank Luppino, President and CEO of Remedium; “The selection of our abstract for a podium presentation is an important milestone highlighting the progress we have made to date developing this novel treatment”.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium announces acceptance of abstract for podium presentation at ORS – 11/22

      BOSTON, Nov 15, 2022 - Remedium Bio, a biotechnology company developing a lead candidate disease modifying gene therapy for the treatment of Osteoarthritis (OA) announced today the acceptance of an abstract titled “AAV2-hFGF18 Increases Cartilage Thickness and Promotes Hyaline Cartilage Anabolism” for the Orthopedic Research Society (ORS) Conference. The 2023 ORS meeting will take place February 10th through 14th in Dallas Texas. Remedium’s abstract was selected to be presented at the Podium Spotlight Session on February 13th, highlighting therapeutic delivery to joints. The work presented will review Remedium’s progress in the development of a novel gene therapy for the treatment of OA, which is the only single-injection treatment potentially capable of reversing cartilage loss, based on the clinically proven mechanism of FGF18.

      Dating back to 1954, the Orthopedic Research Society is a global organization focused on musculoskeletal research. Today, the ORS consists of over 4000 members in nearly 50 countries, representing researchers, clinicians, and veterinarians. “We are very excited to have been accepted to present our abstract reviewing the progress made to date in the development of our FGF18 gene therapy treatment for Osteoarthritis at the 2023 ORS” said Frank Luppino, President and CEO of Remedium; “The selection of our abstract for a podium presentation spotlight session is an important milestone highlighting the progress we have made to date”.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium appoints Richard Hague to Board of Directors – 11/22

      BOSTON, Nov 8, 2022 – Remedium Bio, Inc., a biotechnology company developing novel gene therapies for large unmet needs, today announced the appointment of Richard Hague to its Board of Directors. Mr. Hague is an accomplished biotechnology executive with extensive multi-discipline experience in rheumatology and with regenerative therapies. "Richard is a highly valued addition to the Remedium team, and his background and expertise across three decades in the industry, with many successes in osteoarthritis and regenerative medicine, will help guide Remedium’s strategy and portfolio development as we embark on the next phase of our growth” said Frank Luppino, CEO of Remedium. "We welcome Richard to our Board and look forward to his contributions.”

      “Since inception, Remedium has rapidly built a strong portfolio of novel gene therapies,” said Mr. Hague. “I am excited to join the Board of Directors at this pivotal stage for the company, and eager to help bring the unique advantages of gene therapy to the treatment of osteoarthritis.”

      Mr. Hague is currently the President and Chief Executive Officer of PolarityTE, a regenerative medicine company developing its lead cell therapy product for the treatment of complex wounds. Before joining PolarityTE, Mr. Hague was the Chief Commercial Officer at Anika Therapeutics, where he led all global commercial activities and had oversight of the R&D and Clinical Research functions. He spent a significant portion of his career at Genzyme and later Sanofi (following Sanofi’s acquisition of Genzyme), where he held positions of increasing responsibility, culminating in his role as VP/General Manager of Sanofi’s Cell Therapy and Regenerative Medicine Business Unit. While at Genzyme, Richard played an integral role in the launch and adoption of the first autologous cell therapy products used in orthopedics and burns. Subsequently, he has led the development and launch of innovative products in multiple markets via the CBER and CDRH regulatory pathways.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium to showcase company at the Canadian Stock Exchange Tech Tuesday – 10/22

      BOSTON, Oct 20, 2022 – Remedium Bio is excited to announce that the company has been invited to showcase its innovative flagship potentially disease modifying gene therapy for Osteoarthritis at the Canadian Stock Exchange (CSE) Tech Tuesday webinar, October 25th. The Tech Tuesdays webinars are sponsored by the CSE and designed to spotlight up-and-coming public and private companies that are shaking up the technology industry. The upcoming event will focus on innovations in orthopedic medicine and highlight Remedium’s progress on its lead candidate for Osteoarthritis.

      “We are very excited to have been invited to present at the CSE’s Tech Tuesday webinar” said Frank Luppino, President and CEO of Remedium Bio. “The event provides an opportunity to showcase our innovative rheumatology portfolio for a new audience interested in cutting edge orthopedic innovation”.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium invited to present at the Stony Brook 2022 Life Sciences Summit - 10/22

      BOSTON, Oct 5, 2022 – Remedium is excited to announce that the company has been invited to present at the 2022 Life Sciences Summit, organized by the Center for Biotechnology, Stony Brook University. The Life Sciences Summit is an investor and business development conference showcasing professionally managed, private companies at the Pre-Clinical through Phase-IIa stage of development. The two-day program will feature corporate presentations by promising young companies with transformative science that targets clinical unmet needs. The Showcase Sessions will begin on Oct 17, with the event taking place virtually on November 2nd and 3rd.

      “We are honored to have been invited to present at the 2022 Life Sciences Summit for the second year in a row” said Frank Luppino, President and CEO of Remedium Bio. “Having generated in vivo proof of concept data on our lead candidate disease modifying gene therapy for Osteoarthritis, and advanced several pipeline candidates to preclinical efficacy, we look forward to showcasing our progress with industry leaders and investors”.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium Bio announces successful $2.3M Expanded Seed raise - 8/22

      BOSTON, Aug 15, 2022 - Remedium Bio, Inc., a biotechnology company developing novel gene therapies, today announced that it has closed more than $2.3M in its expanded seed round financing. Funding from the raise is being used to study Remedium’s lead product, a single-injection gene therapy potentially capable of reversing cartilage loss, in a collaboration with Tufts University School of Medicine scientists researching rheumatic disorders. The financing was led by Sherwood Ventures and included participation from, LongevityTech.Fund, Primo Medical Group, Angel Star Ventures, Apis Health Angels, MicroVentures, and Guindy Alumni Angels.

      Remedium’s lead candidate is the only single injection gene therapy based on the clinically proven anabolic mechanism of FGF18, which has demonstrated the ability to reverse cartilage loss in a placebo controlled, multi-center, randomized clinical trial. Osteoarthritis is the largest unmet need in Rheumatology, presenting a market of $37B with no currently approved therapies capable of slowing or reversing disease progression. Remedium’s novel solution offers the potential to arrest disease progression after a single injection and promote restoration of a more natural, youthful phenotype of articular cartilage.

      “Our technology has the potential to reverse years of age-related cartilage loss, for a disease that currently has no approved therapeutic treatments capable of slowing or reversing progression” said Frank Luppino, President and CEO of Remedium Bio, Inc. “We are extremely excited about the progress made to date, and believe that our gene-augmentation technology can be translated to a number of other age-related pathologies with no currently available disease-modifying options.”

      Remedium was founded by orthopedics industry veterans with proven track records of developing leading therapeutics at companies ranging from start-ups to Fortune 500. Remedium has attracted a number of academic collaborators and medical KOLs to its advisory board including Dr. Timothy McAlindon, MD, MPH, Chief of the Division of Rheumatology at Tufts Medical Center, Professor at Tufts University School of Medicine; Dr. Anastassios Pittas, MD, MS, Chief of the Division of Endocrinology, Diabetes, and Metabolism and Co-Director of the Diabetes and Lipid Center at Tufts Medical Center, Professor at Tufts University School of Medicine; Dr. Jeff Ellsworth, PhD, the pioneer of rhFGF18 technology and CSO of Recardia Therapeutics; Dr. Li Zeng PhD, MA, MS, BA Associate Professor Immunology at Tufts University School of Medicine; and Dr. Kai Zou PhD, Assistant Professor, Department of Exercise and Health Sciences, at the University of Massachusetts, Boston.

      Remedium’s pipeline includes therapeutic indications in Osteoarthritis, Diabetes, Stroke, and other large unmet clinical needs.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium announces abstract acceptance for the ASBMR - 8/22

      BOSTON, Aug 8, 2022 - Remedium Bio, a biotechnology company developing a lead candidate disease modifying treatment for Osteoarthritis (OA), today announced the acceptance of an abstract entitled “Characterization of a Novel FGF18 Gene Therapy for the Treatment of Osteoarthritis” for the 2022 Annual American Society of Bone and Mineral Research (ASBMR) meeting. This year’s ASBMR will take place in Austin Texas on September 9th through 12th as an in-person live event. The work presented will highlight Remedium’s progress in the development of a novel gene therapy for the treatment of OA, which is the only single-injection treatment potentially capable of reversing cartilage loss in OA, based on the clinically proven mechanism of FGF18. The American Society for Bone and Mineral Research is a professional, scientific, and medical society established in 1977 with a current membership of over 4,000 worldwide scientists and clinical researchers representing the fields of orthopedics, rheumatology, and pharmacology.

      “We are honored to have been accepted to present our abstract reviewing the progress made to date in the development of our FGF18 gene therapy treatment for Osteoarthritis at the 2022 ASBMR” said Frank Luppino, President and CEO of Remedium, “We have been additionally invited to present a plenary poster on the first day of the event and are looking forward to sharing our findings at this prestigious forum”.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium’s abstract accepted for the Next Generation Gene Therapy Vectors Summit - 07/22

      BOSTON, Jul 12, 2022 - Remedium Bio, a biotechnology company developing innovative gene therapies, today announced the acceptance of an abstract entitled “Novel High Efficiency Gene Delivery System for Human Primary Preadipocytes and Adipocytes” for the presentation of a poster at the 2nd Annual Next Generation Gene Therapy Vectors Summit in Boston. The work presented will highlight Remedium’s progress in the development of a novel gene delivery technology for use in its Type 2 Diabetes program. This technology is being evaluated in a collaboration at the University of Massachusetts Boston, with Professor Kai Zou’s laboratory, and is intended to support a number of therapeutic indications in Remedium’s pipeline.

      The 2nd Annual Next Generation Gene Therapy Vectors Summit is taking place in Boston on July 18th to 20th, bringing together C-suite leaders, R&D experts, and Business Development professionals from Boston’s leading pharma and biotech companies. “We are excited to present data highlighting the progress on our gene delivery technology”, said Frank Luppino, President and CEO of Remedium; “The Next Generation Gene Therapy Vectors Summit is an important milestone for Remedium, as this technology potentially enables treatments in a number of therapeutic indications.”

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium announces abstract acceptance for the 4th Longevity Therapeutics Summit - 05/22

      BOSTON, May 25, 2022 - Remedium Bio announced today the acceptance of its abstract entitled “Novel FGF-18 Gene Therapy for the Treatment of Osteoarthritis” for presentation of a poster at the 4th Annual Longevity Therapeutics Summit. The poster will present results from preclinical studies of Remedium’s gene therapy for the treatment of Osteoarthritis (OA). FGF18 has been shown to result in structural improvement in OA patients in a Phase 2, placebo controlled, randomized clinical trial. Remedium’s novel gene therapy is a first in class, single-injection, potentially disease-modifying OA treatment, based on the proven chondroregenerative mechanism of FGF-18. Osteoarthritis is the most common form of arthritis and the largest unmet need in rheumatology, affecting an estimated 500 million people worldwide. Currently, there are no approved disease-modifying OA treatments capable of slowing or reversing disease progression.

      The Longevity Therapeutics Summit is taking place in San Francisco on Jun 28th to 30th, bringing together over 100 leading biotech and pharma drug developers, academics, and investors. “We are excited to present data demonstrating proof of concept and the potential unique benefits of our novel gene therapy”, said Frank Luppino, President and CEO of Remedium; “The Longevity Therapeutics Summit is an important milestone for Remedium, and is the first in a series of presentations highlighting the encouraging data being generated on our potentially disease modifying treatment for Osteoarthritis.”

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium partners with the pioneer of FGF18 use for Osteoarthritis - 04/22

      BOSTON, Apr 7, 2022 - Remedium is excited to announce the appointment of Dr. Jeff L. Ellsworth as a scientific advisor for the company’s Rheumatology portfolio. Dr. Ellsworth led the R&D team that originally discovered FGF18’s ability to regenerate cartilage and alleviate infarct-induced injury in an animal model of stroke. He has led several R&D functions at companies including CV Therapeutics, ZymoGenetics, Moderna, and Homology Medicines, and is a renowned authority on Osteoarthritis therapeutics in general and the FGF18 protein specifically. Jeff is also a sought after consultant with a successful track record of providing strategic guidance to emerging biotechnology companies. Jeff holds a PhD in Pharmacology and Cell Biophysics from the University of Cincinnati College of Medicine and a Bachelor of Science in Chemistry from the Indiana University Bloomington. Upon completion of his dissertation defense, Jeff spent a number of years as a post-doctoral fellow at Stanford University School of Medicine researching lipoprotein receptors and lipid metabolism.

      "Jeff is a perfect addition to Remedium’s team of advisors given his pivotal role in the discovery of FGF18’s regenerative potential, and strong track record developing a number of highly impactful regenerative therapies" said Frank Luppino, CEO of Remedium Bio. "Jeff will add significant value to Remedium’s R&D activities, including our lead candidate and pipeline products, and we are extremely excited to partner with him.”

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium accepted into the P4 Precision Medicine Accelerator Program - 03/22

      BOSTON, Mar 3, 2022 - Remedium Bio, Inc. is pleased to announce that the company has been accepted into the P4 Precision Medicine Accelerator Program, a collaboration of UCL, London’s Global University, and Capital Enterprise, the UK’s largest startup ecosystem. Remedium has also been accepted into the sister program, P4SY, focused specifically on collaborations in the South Yorkshire region, the location chosen for one of three Gene Therapy Innovation & Manufacturing Centers to be established in the UK to foster advances in precision medicine.

      “We are excited to participate in these two accelerator programs” said Frank Luppino, CEO of Remedium Bio. “Accessing this world-class entrepreneurship network and burgeoning gene therapy and precision medicine ecosystem will help Remedium increase awareness of our novel gene therapy pipeline, expand access to potential collaborators, and provide access to a network of potential strategic partners.”

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium appoints Dr. Li Zeng as Scientific Advisor Rheumatology - 02/22

      BOSTON, Feb 24, 2022 - Remedium is excited to announce the appointment of Dr. Li Zeng, Associate Professor of Immunology as a scientific advisor for the company’s Rheumatology portfolio. Dr. Zeng currently holds the position of Associate Professor of Immunology at the Graduate School of Biomedical Sciences at Tufts University. She holds a PhD and MA in Cell & Molecular Biophysics from Columbia University with Postdoctoral training at the Harvard Medical School, an MS in Biochemistry from Tsinghua University, and a BA in Plant Physiology & Biochemistry from the Beijing Agricultural University. Currently, Dr. Zeng leads an integrated research laboratory at the Tufts University, Graduate School of Biomedical Sciences focusing on Osteoarthritis research. Her laboratory has generated high-impact publications in journals including Nature Scientific Reports, Nature Laboratory Investigations, Development, Journal of Clinical Investigations, and Osteoarthritis and Cartilage.

      "We are extremely excited to partner with Dr. Li Zeng in this important advisory role, supporting our lead candidate Rheumatology gene therapy" said Frank Luppino, CEO of Remedium Bio. "Dr. Zeng is a world-renowned authority who brings a wealth of scientific and mechanistic knowledge to the company enabling further validation of our potentially disease modifying gene therapy for Osteoarthritis”.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium announces research agreement in Diabetes with UMass Boston - 01/22

      BOSTON, Jan 10, 2022 - Remedium Bio, Inc., a biotechnology company developing novel gene therapies, is pleased to announce it has entered into a Sponsored Research Agreement with the University of Massachusetts Boston to complete pre-clinical efficacy studies on Type 1 and Type 2 Diabetes pipeline candidates. The collaboration will evaluate platform technology for the treatment of Diabetes, with translational potential to the broader Remedium pipeline of single-injection potentially disease-modifying gene therapies. The research is being led by Dr. Kai Zou, PhD, Assistant Professor at the Department of Exercise and Health Sciences under the Robert and Donna Manning College of Nursing and Health Sciences at the University of Massachusetts Boston. Dr. Zou’s laboratory has expertise in characterizing metabolic dysfunction associated with Diabetes and has extensive know-how in the fields of endocrine dysregulation, insulin resistance, impaired glucose metabolism, and associated molecular pathophysiological mechanisms. Dr. Zou has extensive expertise in endocrinology having generated high-impact publications in journals including the Journal of Physiology, Surgery, Physiological Genomics, and International Journal of Obesity.

      “The initiation of this research program is a transformational milestone for Remedium” said Frank Luppino, CEO of Remedium Bio. “Through this partnership, Remedium will expand its development portfolio and validate our gene-therapy dose-adjustment platform, which has broad therapeutic applicability beyond the currently targeted indications”.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium Bio appoints Dr. Alexey Seregin as Vice President of R&D - 11/21

      BOSTON, Nov 29, 2021 - Remedium Bio is pleased to announce the appointment of Dr. Alexey Seregin as Vice President of Research and Development. Dr. Seregin is a seasoned leader who brings more than 15 years of experience in the fields of molecular virology and gene therapy to Remedium. He has extensive experience developing viral and non-viral gene therapies in several therapeutic areas including neurodegenerative, neuromuscular, hematologic, metabolic, and gastrointestinal disorders.

      Dr. Seregin brings a strong track record to Remedium Bio, leading a number of high-prolife gene therapy programs at his most recent appointment with Takeda R&D. Previously, Dr. Seregin led Research and Development programs at Biogen, Solid Biosciences, and Bioverativ. Holding a Doctor of Philosophy from The University of Texas Medical Branch at Galveston, Dr. Seregin is the inventor on a number of issued patents covering the development of novel gene therapy technologies and has an extensive list of peer-reviewed publications.

      “We are excited to welcome Dr. Seregin to Remedium Bio” said Frank Luppino, Remedium’s President and CEO. “Alexey is deeply experienced in developing gene therapies and has the technical skillset and scientific depth to enable Remedium’s pipeline of gene therapies targeting diseases with significant unmet needs.”

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium enters collaboration with leading Rheumatology laboratory - 09/21

      BOSTON, Sep 15, 2021 - Remedium Bio, Inc., a biotechnology company developing novel gene therapies, is proud to announce it has entered into a Sponsored Research Agreement with Tufts University’s foremost Rheumatology laboratory to complete pre-clinical efficacy studies on Remedium’s lead gene therapy candidate, a single-injection potentially disease-modifying Osteoarthritis treatment. The research is being led by Dr. Li Zeng, PhD, Associate Professor of Immunology at Tufts University School of Medicine, whose laboratory has developed in vitro, ex vivo, and in vivo testing capabilities for Osteoarthritis (OA). Dr. Zeng is well-known for her extensive expertise in preclinical Rheumatology. Her laboratory has generated high-impact publications in journals including Nature Scientific Reports, Nature Laboratory Investigations, Development, Journal of Clinical Investigations, and Osteoarthritis and Cartilage.

      “The initiation of this research program is a significant milestone for Remedium, and will provide compelling data on our unique approach to the treatment of Osteoarthritis” said Frank Luppino, CEO of Remedium Bio. “Through this partnership, Remedium aims to characterize the functionality of its lead candidate in a range of in vitro, ex vivo, and in vivo efficacy models that will help advance its lead candidate toward IND readiness”.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium appoints Dr Tim McAlindon as Scientific and Medical Advisor - 07/21

      BOSTON, Jul 12, 2021 - Remedium is excited to announce that Dr. Timothy McAlindon, MD, MPH is serving as a scientific and medical advisor for the company’s Rheumatology portfolio. Dr. McAlindon is the Chief of the Division of Rheumatology at the Tufts Medical Center and Professor of Medicine at Tufts University School of Medicine. He is a recognized Key Opinion Leader in Rheumatology, having led the American College of Rheumatology (ACR) Rheumatoid Arthritis (RA) Clinical Treatment Guideline Literature Review Team and chaired the Osteoarthritis Research Society International (OARSI) Treatment Guideline Development Committee. Dr. McAlindon received his Doctorate in of Medicine and Bachelor of Medicine from the University of Southhampton Medical School, his MPH from Boston University School of Public Health, and completed medical training at the Bristol Royal Infirmary, and St. Thomas' Hospital in London, and the Royal United Hospital in the UK. Tim is board certified in Internal Medicine and Rheumatology and is a recipient of a number of prestigious honors and awards including Top Doctor from Boston Magazine and the U.S. News & World Report, 2018 Distinguished Clinical Research Achievement Award from the Clinical Research Forum, as well as the ACR REF Amgen Wyeth Rheumatology Fellowship Training Award. Dr. McAlindon is an author of numerous scientific publications in a broad range of high-impact factor journals including the Journal of the American Medical Association (JAMA) and Annals of Internal Medicine with a research focus in Rheumatoid and Osteoarthritis. "We are extremely excited to partner with Dr. Tim McAlindon in this important advisory role, supporting our lead candidate Rheumatology gene therapy" said Frank Luppino, CEO of Remedium Bio. "Tim is a world-renowned authority who brings a wealth of scientific, regulatory, and clinical experience that enables further validation of our exciting pipeline".

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium appoints Dr Anastassios Pittas as Scientific and Medical Advisor - 06/21

      BOSTON, Jun 30, 2021 - Remedium Bio, Inc. is extremely excited to announce that Dr. Anastassios Pittas will serve as a Scientific and Medical Advisor on the company’s Endocrinology portfolio. Dr. Pittas is the Chief of the Division of Endocrinology, Diabetes, and Metabolism and Professor of Medicine at Tufts University. He is a recipient of a number of prestigious honors and awards including multiple consecutive Top Doctor awards from Boston Magazine, Biomedical Research Exemplar Award which honors individuals doing high-quality, high-impact, federally-funded research who also maintain an impressive reputation for professionalism and integrity in their work as well as the Donna Seto-Young Award, which recognizes meritorious achievement in the advancement of science, education, practice of medicine or improvement of human health and well-being. Dr. Pittas holds a Bachelor of Science in Biology from MIT, a Master of Science in Clinical Research from the Sackler School of Biomedical Sciences at Tufts University, an MD from the Weill Medical College of Cornell University, completed his Internal Medicine Residences at the New York Presbyterian Hospital, and a Fellowship in Endocrinology, Diabetes, and Metabolism at the Tufts Medical Center. "Partnering with Dr. Pittas brings significant subject matter expertise in Endocrinology and helps Remedium validate its multiple Diabetes pipeline candidates from a clinical perspective" said Frank Luppino, CEO of Remedium Bio. "We are extremely excited to be working with Dr. Pittas and are looking forward to evaluating our novel and proprietary approaches to treating Type 1 and Type 2 diabetes with gene therapy".

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium Bio appoints Alex Goraltchouk as Chief Operating Officer - 06/21

      BOSTON, Jun 11, 2021 - Remedium Bio, Inc. is excited to announce the appointment of Alex Goraltchouk as the Chief Operating Officer. Alex brings 16 years industry experience developing and industrializing biologics and gene therapies at companies including Allergan, Biogen, and Regeneron. Alex’s experience, which ranges from start-up to Fortune 500 spans the development, industrialization, and launch of a number of market-dominant brands including Spinraza (SMA antisense oligonucleotide), Benepali (TNF inhibitor), Kevzara (IL-6 inhibiting monoclonal antibody), and Praluent (PCSK9 inhibiting monoclonal antibody). With a focus on endocrinology, rheumatology, and cardiovascular diseases, Alex’s functional expertise allow the company to further strengthen the R&D, Operations, Quality, and Project Management organizations. Holding a Bachelor in Materials Engineering and a Master in Chemical Engineering from the University of Toronto, an MBA and Master of Science in Finance from Indiana University, and a Master of Microbiology and Cell Sciences from the University of Florida, Alex possesses a broad scientific background in several disciplines that add significant value to Remedium’s development efforts. Alex is a Cornell certified Six Sigma Black Belt, holds an MIT MicroMasters in Supply Chain Management, a Bioinformatics MicroMasters from the University of Maryland University College, a Stanford Certificate in Genetics and Genomics, and is a Certified Project Management Professional enabling the company’s scientific advancement and operational efficiency. “I am delighted to welcome Alex to Remedium” said Frank Luppino, Remedium’s President and CEO. “Alex has broad technical capabilities and demonstrated leadership experience that align perfectly with Remedium’s mission to develop novel gene therapies for diseases with significant unmet needs.”

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium Bio, Inc. secures Seed Round of financing - 04/21

      BOSTON, Apr 16, 2021 - Remedium Bio, Inc. a Boston based biotechnology company focused on developing curative therapies in a broad range of diseases, announced today the funding of the Seed Series Financing round, raising over $1.2 million to build out the management team and advance the lead candidate molecules through pre-clinical efficacy.

      With this financing, Remedium shareholders will benefit from significant value creation via the advancement of multiple molecules through discovery and pre-clinical development within the company's core platforms including gene delivery, growth factor expression, and disease reversal. Proceeds from Remedium's financing will be used to initiate operations, secure key leadership personnel, complete in vitro and in vivo efficacy studies for our lead program, and initiate in vitro efficacy for the second pipeline candidate. Further to the addition of top talent to Remedium's team, the company will use the funds to secure key strategic partnerships with academic institutions and suppliers, hire a world-renowned scientific advisory board, and support a number of IND-enabling studies.

      "We are highly excited about securing this financing for Remedium, a foundational investment which will enable the company to build the infrastructure and create the data to validate the pre-clinical biology of our lead candidates," said Frank Luppino, President and CEO of Remedium Bio, Inc.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium to present at the 2020 Octane OC LaunchPad Investment Forum - 10/20

      BOSTON, Sep 3, 2020 - Remedium Bio, Inc. is excited to be selected as the LaunchPad Finalist at the Octane OC MedTech Innovation Forum, 2020. "We are delighted to have been invited to present in the Octane OC MedTech Innovation Forum 2020 as part of the finalist companies! This is indeed a high vote of confidence for our technology and business model." - said Frank Luppino, President and CEO of Remedium Bio. "Our mission to cure dibilitating diseases by combining proven therapeutic modalities in a novel, innovative approach presents a unique opportunity for our shareholders and potential investors; we are excited to share our progress to date at the Octane OC 2020 forum!". Remedium Bio, a Boston based gene therapy start-up, is focused on developing curative therapies in a broad range of diseases is advancing it's lead candidate toward IND-readiness in 2022.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium Bio appoints Frank Luppino as President and CEO - 01/20

      BOSTON, Jan 9, 2020 - Remedium Bio, Inc. is delighted to announce the appointment of Frank Luppino as President and Chief Executive Officer, Treasurer and Chairman of the Board starting Jan 10, 2020. Mr. Luppino brings over 25 years product development, industrialization, and commercial launch experience at public and private companies including Anika Therapeutics, Bionostics, and Black & Veatch. Serving as the Chief Operating Officer at Anika Therapeutics, Frank has extensive demonstrated experience leading R&D, Operations, Regulatory, Clinical, and Supply Chain organizations. Further to his broad cross-functional expertise, Frank was instrumental at leading the launch of a series of blockbuster biologic, cell therapy, and drug-device combination products including Cingal®, Monovisc®, Hyalofast®, and Tactoset®. Finally, Frank’s experience spans a broad range of therapeutic areas including rheumatology, soft tissue regeneration, and ophthalmology, bringing significant business, technical, clinical, and regulatory expertise to the company.

      “Remedium is at an exciting, foundational stage of its corporate evolution, with a highly innovative pipeline of disruptive, curative therapies, Remedium is well positioned to successfully advance these high-value product candidates to the clinic and beyond, creating value for our shareholders,” said Mr. Luppino. “I look forward to building the Remedium team and advancing our lead candidates through pre-clinical development and driving business value creation.” 

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

investor faq

  • what we do
    Remedium bio at a glance

    Remedium Bio, Inc. is a biotechnology company focused on the development of curative therapies for a broad range of pathologies. Our people passionately believe that any disease can be cured and are tirelessly working to deliver therapies to patients for a broad range of therapeutic categories. Grounded in our premise, Remedium scientists discover and develop therapies by appropriately matching treatment modalities with specific disease pathophysiology to replace or augment missing, degenerated, or damaged tissues one treatment at a time.

    Our team is located in the Boston area, a modern-day Mecca of Biotechnology. We are founded on the vision of changing lives via curative breakthroughs with a firm scientific foundation with the goal of creating a company that changes the way we think about treating disease.

  • Our people
    Our people - the Remedium team

    Our people are at the core of everything we do, they are what makes Remedium special, what makes our innovations unique, the driving force behind our vision that any disease can be cured. With this in mind, Remedium strives to hire the most talented professionals in the industry, the brightest minds with the most open hearts - adventurers with an inner child, glass half full, looking at the world through rose colored glasses.

    As a company we firmly believe in diligently and persistently investing in our people, supporting training, education, and growth, every step of their way. Inclusion and diversity are at our core, acceptance of all cultures and ideas is the Remedium gold standard, and it is upon this edifice that we venture to build a company to cure one disease at a time - a brilliant today for a better tomorrow.

  • Our science
    The ideas that drive our therapies

    Science is at the foundation of everything we do at Remedium - a uniting principle that innovation, data-driven analysis, and a culture conducive to open discussion that promotes a healthy debate is essential to ideation and delivery of the ideas as treatments to patients. At the core of our values are the principles that all decisions should be supported by data, all scientific ideas are worthy of careful consideration, and turning ideas into medicine is the most noble pursuit of humanity.

  • Ethical commitment
    A high ethical and social bar

    At Remedium, we are firmly committed to upholding the highest ethical standards including integrity, honesty and truthfulness, multicultural and intellectual diversity, respect for all ideas and individuality, inclusion, transparency, freedom of expression, and respect for the dignity and rights of all individuals. Furthermore, we strive to achieve the highest standards in Corporate Social Responsibility and create a sustainable future for our People, Community, and Environment.

    Remedium and our highly-valued team strives to exercise this commitment in everything we do. As members of the Biotechnology community we feel a heightened need to hold ourselves to the highest standards of ethical responsibility in addition to fully abiding by international, federal, and state laws and regulations, following internal policies and industry best practices wherever and whenever possible.

Background Image

remedium bio

Learn more about why we believe that any disease can be cured.

about us

Get In Touch

We are always interested in starting a new conversation and are looking forward to hearing from you. Thank you in advance for your inquiry and please have a wonderful day!


1116 Great Plain Ave, Suite 203
Needham, MA
02492


E: info@remedium-bio.com
P: +1 (978) 467 5217